Symposium Session Summaries: Sessions 8.4 to 13.3

12th Annual North American Cystic Fibrosis Conference. Montreal, Quebec, Canada. October 15-18, 1998

[1]  B. Strandvik,et al.  Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis. , 2008, Liver.

[2]  Christina H. Park,et al.  Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. , 1998, The Journal of clinical investigation.

[3]  G. Herberth,et al.  Catalase, myeloperoxidase and hydrogen peroxide in cystic fibrosis. , 1998, The European respiratory journal.

[4]  I Wilmut,et al.  Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. , 1997, Science.

[5]  M. Knowles,et al.  Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. , 1997, The Journal of clinical investigation.

[6]  Johann Hofmann,et al.  The potential for isoenzyme‐selective modulation of protein kinase C , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  A. Harris,et al.  Cystic Fibrosis of the Pancreas: Involvement of MUC6 Mucin in Obstruction of Pancreatic Ducts , 1997, Molecular medicine.

[8]  B. Winklhofer-Roob,et al.  Plasma vitamin C concentrations in patients with cystic fibrosis: evidence of associations with lung inflammation. , 1997, The American journal of clinical nutrition.

[9]  R. Frizzell,et al.  Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca2+-induced arachidonic acid release by epithelial cells. , 1997, DNA and cell biology.

[10]  T. Ganz,et al.  Purification and characterization of defensins from cystic fibrosis sputum , 1997, Inflammation Research.

[11]  James M. Wilson,et al.  Human β-Defensin-1 Is a Salt-Sensitive Antibiotic in Lung That Is Inactivated in Cystic Fibrosis , 1997, Cell.

[12]  C. Vogelmeier,et al.  Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity. , 1996, Chest.

[13]  B. Strandvik,et al.  Prostanoid biosynthesis in patients with cystic fibrosis. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[14]  T. Tetley,et al.  Secretory leukoprotease inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation. , 1996, Thorax.

[15]  A. Christophe,et al.  Current knowledge on fatty acids in cystic fibrosis. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[16]  S. Suter,et al.  Neutrophil Elastase/α1-Proteinase Inhibitor Complex Levels Decrease in Plasma of Cystic Fibrosis Patients during Long-Term Oral β-Carotene Supplementation1 , 1996, Pediatric Research.

[17]  M. V. van’t Hof,et al.  Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. , 1996, The American journal of clinical nutrition.

[18]  E. Greenberg,et al.  Cystic Fibrosis Airway Epithelia Fail to Kill Bacteria Because of Abnormal Airway Surface Fluid , 1996, Cell.

[19]  I. Wilmut,et al.  Sheep cloned by nuclear transfer from a cultured cell line , 1996, Nature.

[20]  L. Tsui,et al.  Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor , 1996, Nature Genetics.

[21]  J. Price,et al.  Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. , 1996, The European respiratory journal.

[22]  N. Brown,et al.  Fatty acid pool size in plasma lipoprotein fractions of cystic fibrosis patients. , 1995, The American journal of clinical nutrition.

[23]  M. V. van’t Hof,et al.  Impaired resistance to oxidation of low density lipoprotein in cystic fibrosis: improvement during vitamin E supplementation. , 1995, Free radical biology & medicine.

[24]  M. V. van’t Hof,et al.  Enhanced resistance to oxidation of low density lipoproteins and decreased lipid peroxide formation during beta-carotene supplementation in cystic fibrosis. , 1995, Free radical biology & medicine.

[25]  J. Lunec,et al.  Oxidative damage to DNA in patients with cystic fibrosis. , 1995, Free radical biology & medicine.

[26]  D. Hill,et al.  Molecular analysis of the ovine cystic fibrosis transmembrane conductance regulator gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Peri,et al.  Cystic fibrosis and phosphatidylcholine biosynthesis. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[28]  F. Kelly,et al.  Role of free radicals in the pathogenesis of cystic fibrosis. , 1994, Thorax.

[29]  R. Crystal,et al.  Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. , 1994, American journal of respiratory and critical care medicine.

[30]  A. Harris,et al.  Analysis of mutations and alternative splicing patterns in the CFTR gene using mRNA derived from nasal epithelial cells. , 1994, Human Molecular Genetics.

[31]  B. Winklhofer-Roob.  Oxygen free radicals and antioxidants in cystic fibrosis: the concept of an oxidant‐antioxidant imbalance , 1994, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[32]  R. Crystal,et al.  Systemic deficiency of glutathione in cystic fibrosis. , 1993, Journal of applied physiology.

[33]  R. Crystal,et al.  Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. , 1993, The American review of respiratory disease.

[34]  M. Kaliner,et al.  Estimation of nasal epithelial lining fluid using urea as a marker. , 1993, The Journal of allergy and clinical immunology.

[35]  R. F. Hoyt,et al.  Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid. , 1993, Journal of applied physiology.

[36]  G. Béréziat,et al.  Increase of bradykinin-stimulated arachidonic acid release in a delta F508 cystic fibrosis epithelial cell line. , 1993, Biochimica et biophysica acta.

[37]  F. Kelly,et al.  Reduced Free-Radical-Trapping Capacity and Altered Plasma Antioxidant Status in Cystict Fibrosis , 1993, Pediatric Research.

[38]  C. D. Cox,et al.  Interaction of the Pseudomonas aeruginosa secretory products pyocyanin and pyochelin generates hydroxyl radical and causes synergistic damage to endothelial cells. Implications for Pseudomonas-associated tissue injury. , 1992, The Journal of clinical investigation.

[39]  R. Crystal,et al.  Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. , 1992, The Journal of clinical investigation.

[40]  A. Harris,et al.  Expression of the cystic fibrosis gene in human development. , 1991, Development.

[41]  R. Crystal,et al.  Aerosol α1 -antitrypsin treatment for cystic fibrosis , 1991, The Lancet.

[42]  R. Crystal,et al.  Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. , 1991, The Journal of clinical investigation.

[43]  R. F. Hoyt,et al.  Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. , 1990, Journal of applied physiology.

[44]  C. D. Cox,et al.  Possible role of bacterial siderophores in inflammation. Iron bound to the Pseudomonas siderophore pyochelin can function as a hydroxyl radical catalyst. , 1990, The Journal of clinical investigation.

[45]  W. Guggino,et al.  Direct modulation of secretory chloride channels by arachidonic and other cis unsaturated fatty acids. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[46]  B. Strandvik,et al.  Effect on renal function of essential fatty acid supplementation in cystic fibrosis. , 1989, The Journal of pediatrics.

[47]  S. Weiss.  Tissue destruction by neutrophils. , 1989, The New England journal of medicine.

[48]  B. Strandvik,et al.  Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[49]  R. Olver,et al.  Sodium and chloride transport by the tracheal epithelium of fetal, new‐born and adult sheep. , 1986, The Journal of physiology.

[50]  H. K. Harms,et al.  Calcium Metabolism and Cystic Fibrosis: Mitochondrial Abnormalities Suggest a Modification of the Mitochondrial Membrane , 1984, Pediatric Research.

[51]  A. D. Smith,et al.  The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. , 1984, Biochimica et biophysica acta.

[52]  C. Cotton,et al.  Bioelectric properties and ion transport of airways excised from adult and fetal sheep. , 1983, Journal of applied physiology: respiratory, environmental and exercise physiology.

[53]  R. Feigal,et al.  Mitochondrial calcium uptake and oxygen consumption in cystic fibrosis , 1979, Nature.

[54]  J. Hull,et al.  Elemental content of airway surface liquid from infants with cystic fibrosis. , 1998, American journal of respiratory and critical care medicine.

[55]  J. Zieleński,et al.  Cystic fibrosis: genotypic and phenotypic variations. , 1995, Annual review of genetics.

[56]  P. Birrer.  Proteases and antiproteases in cystic fibrosis: pathogenetic considerations and therapeutic strategies. , 1995, Respiration; international review of thoracic diseases.

[57]  P. Baeuerle,et al.  Function and activation of NF-kappa B in the immune system. , 1994, Annual review of immunology.

[58]  J. Gyulay.  Home care for the dying child. , 1989, Issues in comprehensive pediatric nursing.